225 related articles for article (PubMed ID: 34574696)
1. Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
Blum K; Gold MS; Llanos-Gomez L; Jalali R; Thanos PK; Bowirrat A; Downs WB; Bagchi D; Braverman ER; Baron D; Roy AK; Badgaiyan RD
Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574696
[No Abstract] [Full Text] [Related]
2. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.
Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS
J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300
[TBL] [Abstract][Full Text] [Related]
3. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.
Blum K; Chen TJ; Meshkin B; Waite RL; Downs BW; Blum SH; Mengucci JF; Arcuri V; Braverman ER; Palomo T
Med Hypotheses; 2007; 69(5):1054-60. PubMed ID: 17467918
[TBL] [Abstract][Full Text] [Related]
4. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS).
Blum K; Chen TJ; Meshkin B; Downs BW; Gordon CA; Blum S; Mangucci JF; Braverman ER; Arcuri V; Deutsch R; Pons MM
Med Hypotheses; 2007; 68(4):844-52. PubMed ID: 17071010
[TBL] [Abstract][Full Text] [Related]
5. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).
Blum K; Chen TJ; Downs BW; Bowirrat A; Waite RL; Braverman ER; Madigan M; Oscar-Berman M; DiNubile N; Stice E; Giordano J; Morse S; Gold M
Postgrad Med; 2009 Nov; 121(6):176-96. PubMed ID: 19940429
[TBL] [Abstract][Full Text] [Related]
6. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
Blum K; Baron D; McLaughlin T; Gold MS
J Neurol Sci; 2020 Apr; 411():116733. PubMed ID: 32088516
[TBL] [Abstract][Full Text] [Related]
7. Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.
Blum K; Oscar-Berman M; Stuller E; Miller D; Giordano J; Morse S; McCormick L; Downs WB; Waite RL; Barh D; Neal D; Braverman ER; Lohmann R; Borsten J; Hauser M; Han D; Liu Y; Helman M; Simpatico T
J Addict Res Ther; 2012 Nov; 3(5):139. PubMed ID: 23926462
[TBL] [Abstract][Full Text] [Related]
8. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.
Blum K; Chen AL; Chen TJ; Braverman ER; Reinking J; Blum SH; Cassel K; Downs BW; Waite RL; Williams L; Prihoda TJ; Kerner MM; Palomo T; Comings DE; Tung H; Rhoades P; Oscar-Berman M
Theor Biol Med Model; 2008 Nov; 5():24. PubMed ID: 19014506
[TBL] [Abstract][Full Text] [Related]
9. Dopamine and glucose, obesity, and reward deficiency syndrome.
Blum K; Thanos PK; Gold MS
Front Psychol; 2014; 5():919. PubMed ID: 25278909
[TBL] [Abstract][Full Text] [Related]
10. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
[TBL] [Abstract][Full Text] [Related]
11. Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?
Blum K; Raza A; Schultz T; Jalali R; Green R; Brewer R; Thanos PK; McLaughlin T; Baron D; Bowirrat A; Elman I; Downs BW; Bagchi D; Badgaiyan RD
Acta Sci Neurol; 2021 Feb; 4(2):17-24. PubMed ID: 33681869
[TBL] [Abstract][Full Text] [Related]
12. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.
Blum K; Kazmi S; Modestino EJ; Downs BW; Bagchi D; Baron D; McLaughlin T; Green R; Jalali R; Thanos PK; Elman I; Badgaiyan RD; Bowirrat A; Gold MS
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809702
[TBL] [Abstract][Full Text] [Related]
13. Nutrigenomic basis of beneficial effects of chromium(III) on obesity and diabetes.
Lau FC; Bagchi M; Sen CK; Bagchi D
Mol Cell Biochem; 2008 Oct; 317(1-2):1-10. PubMed ID: 18636317
[TBL] [Abstract][Full Text] [Related]
14. Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map?
Downs BW; Chen AL; Chen TJ; Waite RL; Braverman ER; Kerner M; Braverman D; Rhoades P; Prihoda TJ; Palomo T; Oscar-Berman M; Reinking J; Blum SH; DiNubile NA; Liu HH; Blum K
Med Hypotheses; 2009 Sep; 73(3):427-34. PubMed ID: 19450935
[TBL] [Abstract][Full Text] [Related]
15. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Blum K; Febo M; Fried L; Li M; Dushaj K; Braverman ER; McLaughlin T; Steinberg B; Badgaiyan RD
Subst Use Misuse; 2017 Mar; 52(4):535-547. PubMed ID: 28033474
[TBL] [Abstract][Full Text] [Related]
16. Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a Genotrim variant.
Blum K; Chen TJ; Meshkin B; Downs BW; Gordon CA; Blum S; Mengucci JF; Braverman ER; Arcuri V; Varshavskiy M; Deutsch R; Martinez-Pons M
Adv Ther; 2006; 23(6):1040-51. PubMed ID: 17276971
[TBL] [Abstract][Full Text] [Related]
17. Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term.
Blum K; Badgaiyan RD; Braverman ER; Dushaj K; Li M; Thanos PK; Demetrovics Z; Febo M
J Reward Defic Syndr Addict Sci; 2016; 2(1):14-21. PubMed ID: 28317038
[TBL] [Abstract][Full Text] [Related]
18. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.
Blum K; Gold MS
Med Hypotheses; 2011 Apr; 76(4):576-84. PubMed ID: 21306831
[TBL] [Abstract][Full Text] [Related]
19. Sarcopenic obesity and complex interventions with nutrition and exercise in community-dwelling older persons--a narrative review.
Goisser S; Kemmler W; Porzel S; Volkert D; Sieber CC; Bollheimer LC; Freiberger E
Clin Interv Aging; 2015; 10():1267-82. PubMed ID: 26346071
[TBL] [Abstract][Full Text] [Related]
20. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia.
Biolo G; Cederholm T; Muscaritoli M
Clin Nutr; 2014 Oct; 33(5):737-48. PubMed ID: 24785098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
